Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2014-03-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2013年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shenzhen Salubris Pharmaceuticals Co., Ltd. for the fiscal year ending December 31, 2013. It includes specifics on the amount of funds raised, their allocation, usage, project progress, changes in project implementation, and compliance with regulatory requirements. The document references approvals by the China Securities Regulatory Commission and details on fundraising activities, fund storage, and investment projects. It is a specialized report focused on the status and use of raised capital rather than a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and project data, not merely an announcement or certification, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2014-03-24 Chinese
2013年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report (审计报告) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes detailed audited financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and statements of changes in equity for the fiscal year ending December 31, 2013. The document contains the auditor's opinion, management responsibilities, and detailed financial data with notes. The length is substantial (15,000 characters), and it is not merely an announcement or certification but the full audit report with financial statements. Therefore, it fits the category of Audit Report / Information (AR). FY 2013
2014-03-24 Chinese
2013年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2013 年度报告全文" which translates to "2013 Annual Report Full Text" for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, board of directors report, risk factors, business analysis, financial statements, and other comprehensive disclosures. The length is substantial (15,000 characters), and it includes actual financial data, management discussion, and detailed accounting information. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2013
2014-03-24 Chinese
2013年度独立董事述职报告（潘玲曼）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the Year 2013" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, on-site inspections, supervision of internal controls and information disclosure, training, and suggestions for improvement. The content is a detailed report by an independent director on their duties and activities during the year, rather than a general annual report or financial statement. It does not contain financial statements or audit results but focuses on governance and oversight activities by the independent director. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 2681 characters, which is relatively short but contains substantive content about the independent director's role and activities, not just an announcement or notice. Therefore, the classification is MANG with high confidence.
2014-03-24 Chinese
关于公司募集资金年度存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report and special report on the annual deposit and actual use of raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The content includes detailed financial figures on raised funds, their usage, project progress, changes in project implementation, and compliance with regulatory requirements. The document is not a general annual report or earnings release but a specialized audit/verification report focused on the raised funds' management and usage. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific regulatory requirements, excluding full annual reports. The document length (15,000 characters) and detailed financial and project data support this classification with high confidence. FY 2013
2014-03-24 Chinese
第三届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Shenzhen Xintai Pharmaceutical Co., Ltd. It includes approvals of the 2013 annual general manager work report, board work report, 2013 annual report and its summary, profit distribution plan, appointment of a new financial officer, remuneration plans, audit firm reappointment, fundraising usage report, internal control self-assessment report, and a proposal to convene the 2013 annual shareholders meeting. The document references the 2013 annual report multiple times and states that some reports will be submitted to the 2013 annual shareholders meeting for approval. The document is not the annual report itself but a board meeting resolution announcement discussing and approving various reports and proposals related to the 2013 fiscal year. It also includes appointment and remuneration decisions for senior management. Given the content, this is a Board/Management Information filing (MANG) because it primarily announces board meeting resolutions including management appointments and approvals of reports to be submitted to shareholders, rather than the full annual report or other report types. The document length (4896 characters) and detailed meeting resolutions support this classification.
2014-03-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.